To explore the protective effect of sacubitril valsartan combined with metoprolol in treatment of coronary atheroselerotic heart disease (CHD) with chronic heart failure (CHF).
A total of 180 patients with CHD and CHF were randomly divided into intervention group and control group, with 90 cases in each group. The control group were treated with angiotensin-converting enzyme inhibitor or angiotensin Ⅱ receptor antagonist combined with metoprolol, the intervention group were treated with sacubitril valsartan combined with metoprolol for 6 months. Clinical efficacy and major adverse cardiovascular events were compared between two groups. The left ventricular ejection fraction (LVEF), maximum early filling speed/maximum filling speed in late diastole (E/A), left ventricular end systolic diameter (LVESD), left ventricular end diastolic diameter (LVEDD) and left ventricular mass index (LVMI) were measured before and after treatment. The plasma N-terminal brain natriuretic peptide (NT-proBNP), serum cardiac troponin Ⅰ(cTn Ⅰ), creatine kinase isoenzyme (CK-MB), serum creatinine (Scr), cystatin C (CysC) and potassium were determined. The Minnesota living with heart failure questionnaire (MLHFQ) score, Lee's heart failure score and 6 min walking test (6MWT) were measured.
Total effective rate of intervention group was significantly higher than that of control group (P<0.05). After treatment, there was no significant difference in blood pressure and heart rate between two groups (P>0.05), but the LVEF and E/A of intervention group were higher than those of control group, and LVEDD, LVESD, and LVMI were significantly lower than those of control group (P<0.05). After treatment, the levels of NT-proBNP, cTnⅠ, CK-MB and CysC in intervention group were significantly lower than those of control group (P<0.05), but there was no significant difference in Scr and potassium between two groups (P>0.05). After treatment, the 6MWT of intervention group was significantly higher than that of control group, while the MLHFQ and Lee's heart failure scores were significantly lower than those of control group (P<0.05). The follow-up results showed that the readmission rate for heart failure of intervention group were significantly lower than that of control group (P<0.05). The 2-year follow-up results showed that incidence of major adverse cardiovascular events (MACE) of intervention group were significantly lower than that of control group (P<0.05).
Sacubitril valsartan combined with metoprolol can improve the heart and kidney function of patients with CHD and CHF, inhibit left ventricular remodeling, improve exercise endurance and quality of life, and reduce the rate of MACE.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |